On November 4, 2023 sairopa.com – a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system, reported early clinical data on ADU-1604, its proprietary anti-CTLA4 antibody at the SITC (Free SITC Whitepaper) 38th Annual Meeting (Press release, Sairopa, NOV 4, 2023, View Source [SID1234636973]). Data obtained from the ongoing Phase 1 dose-escalation stage in PD1 relapse/refractory melanoma patients (N=17) were presented. ADU-1604 is well tolerated at the dosages tested (25, 75, 225 and 450 mg Q3W). No dose-limiting toxicities or treatment-related severe adverse events have been reported up to now. Pre-clinical data was presented that potentially explains the suggested improved safety profile of ADU-1604 vs. other anti-CTLA4 antibodies. ADU-1604 was shown to dose-dependently increase pharmacodynamic biomarkers, which correlates with early signs of clinical activity. Finally, early clinical efficacy data was reported showing one unusually long stable disease and two ongoing tumor regressions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!